logo
  

Genzyme Reveal Positive Results From Second Phase III Study Of Oral AUBAGIO

Genzyme, a Sanofi company (SNY) Friday announced positive results from the TOWER trial for Treatment and Research in Multiple Sclerosis.

TOWER is a Phase III, multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of AUBAGIO in patients with relapsing MS followed by an open-label extension period.

The company, engaged in the the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years, stzted thzt in the study, once-daily, oral AUBAGIO 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in patients with relapsing forms of multiple sclerosis (MS) compared to placebo.

The company further added that the proportion of patients treated with AUBAGIO who were relapse-free was significantly higher compared to placebo.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Restaurant Association or NRA has urged the U.S. Congress to refill the Restaurant Revitalization Fund or RRF, which is expected to save more than 1.6 million jobs in the restaurant industry hit hard by the surge in Omicron Variant. In a letter to Congress, the association highlighted, based on its survey on 4,200 restaurant operators, the devastating impact so far on the industry... Industrial conglomerate General Electric Co. reported Tuesday a net loss for the fourth quarter compared to a profit last year, hurt by steep debt extinguishment costs and lower revenues. However, adjusted earnings per share topped analysts' expectations, while quarterly revenues missed them. Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin.
Follow RTT